Comparative Pharmacology
Head-to-head clinical analysis: BUTOCONAZOLE NITRATE versus VITUZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTOCONAZOLE NITRATE versus VITUZ.
BUTOCONAZOLE NITRATE vs VITUZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Vituz is an epidermal growth factor receptor (EGFR) inhibitor that binds to the tyrosine kinase domain, blocking downstream signaling pathways involved in cell proliferation and survival.
Intravaginal administration: 100 mg (one applicatorful of 2% cream) once daily for 3 days; or 100 mg (one suppository) once daily for 3 days; or 5 g (one applicatorful of 4% cream) as a single dose.
400 mg orally every 8 hours for 5 days; initiate within 48 hours of symptom onset.
None Documented
None Documented
Terminal half-life is approximately 21–24 hours, supporting once-daily or twice-weekly dosing for vaginal candidiasis.
The terminal elimination half-life is 12-15 hours in patients with normal renal function, allowing twice-daily dosing. In moderate renal impairment (CrCl 30-50 mL/min), half-life extends to 20-28 hours; in severe impairment (CrCl <30 mL/min), it exceeds 40 hours.
Primarily hepatic metabolism with <5% excreted unchanged in urine; fecal elimination accounts for ~30% of metabolites.
VITUZ (vitluzolamide) is primarily excreted via renal elimination as unchanged drug (45-55%) and as the major inactive metabolite M1 (20-30%). Biliary/fecal excretion accounts for 15-20%, primarily as M1. Less than 5% is eliminated via other routes.
Category A/B
Category C
Antifungal
Antifungal